Print Page  Close Window

SEC Filings

S-1/A
VITAE PHARMACEUTICALS, INC filed this Form S-1/A on 08/29/2014
Entire Document
 

        We either have entered or intend to enter into indemnification agreements with each of our directors and executive officers and certain other key employees. The form of agreement provides that we will indemnify each of our directors, executive officers and such other key employees against any and all expenses incurred by that director, executive officer, or other key employee because of his or her status as one of our directors, executive officers, or other key employees, to the fullest extent permitted by Delaware law, our restated certificate of incorporation and our amended and restated bylaws. In addition, the form agreement provides that, to the fullest extent permitted by Delaware law, we will advance all expenses incurred by our directors, executive officers and other key employees in connection with a legal proceeding.

        Reference is made to the underwriting agreement contained in Exhibit 1.1 to this registration statement, indemnifying our directors and officers against limited liabilities. In addition, Section 1.9 of our amended and restated investors' rights agreement (IRA) contained in Exhibit 4.2 to this registration statement provides for indemnification of certain of our stockholders against liabilities described in our IRA.

        We currently carry and intend to continue to carry liability insurance for our directors and officers.

Item 15.    Recent Sales of Unregistered Securities

        The following sets forth information regarding all unregistered securities sold since January 1, 2011 through August 27, 2014:

    (1)
    In 2011, in connection with the closing of a term loan, we issued a warrant to Silicon Valley Bank exercisable for an aggregate of 229,167 shares of our Series D convertible preferred stock, at an exercise price of $1.20 per share. This warrant terminates ten years after the date issued.

    (2)
    In 2011, in connection with the closing of a term loan, we issued two warrants to Oxford Finance LLC, one exercisable for an aggregate of 229,166 shares of our Series D convertible preferred stock and the other exercisable for an aggregate of 229,167 shares of our Series D convertible preferred stock. Both warrants have an exercise price of $1.20 per share and terminate ten years after the date issued.

    (3)
    Under the 2013 Stock Plan, we granted stock options to purchase shares of our common stock to certain of our employees, officers, consultants and advisors, as follows: (a) in 2013, we granted restricted stock units with respect to an aggregate of 9,000,000 shares of our common stock, (b) in 2014, we granted stock options to purchase an aggregate of 285,000 shares of our common stock at an exercise price of $0.16 per share and (c) in 2014, we granted stock options to purchase an aggregate of 7,627,279 shares of our common stock at an exercise price of $0.23 per share.

    (4)
    Under the 2001 Stock Plan, we granted stock options to purchase shares of our common stock to certain of our employees, officers, consultants and advisors, as follows: (a) in 2011, we granted stock options to purchase an aggregate of 6,993,000 shares of our common stock at an exercise price of $0.31 per share, (b) in 2011, we granted a stock option to purchase 50,000 shares of our common stock at an exercise price of $0.33 per share, (c) in 2012, we granted stock options to purchase an aggregate of 20,000 shares of our common stock at an exercise price of $0.33 per share, (d) in 2012, we granted a stock option to purchase 75,000 shares of our common stock at an exercise price of $0.27 per share, (e) in 2013, we granted a stock option to purchase 10,000 shares of our common stock at an exercise price of $0.27 per share, and (f) in 2013, we granted a stock option to purchase 10,000 shares of our common stock at an exercise price of $0.16 per share.

    (5)
    We issued shares of our common stock upon the exercise of stock options, as follows: (a) in 2011 we issued an aggregate of 335,584 shares for an aggregate exercise price of $40,169; (b) in 2012 we issued an aggregate of 528,215 shares for an aggregate exercise price of $52,962; (c) in 2013

II-2